Pfizer vs. Merck and the Future of R&D
This article was originally published in RPM Report
Executive Summary
Two brand new CEOs take very different approaches to address the same problem: what to do about unrealistic expectations for growth in 2012. The different strategies chart different courses through a stressful period. We’ve seen this debate before, and it is hard to argue that either company prevailed last time around.
You may also be interested in...
FDA and the R&D Crisis: Time to Stop the Blame Game
Everyone knows R&D productivity has dipped to levels that threaten the private drug development model, and almost everyone says regulatory hurdles are part of the problem. That isn’t how FDA sees it. One thing is clear: blaming FDA won’t help anyone, so it may be time to pay more attention to FDA’s ideas for solutions rather than continue to point fingers.
Job One for Big Pharma: Repositioning in DC Post-Health Care Reform
How Wall Street’s reaction to the impact of health care reform may help the pharmaceutical industry make sure it pays off in the long run.
The Optics of Health Care Reform
There are plenty of reasons Wall Street doesn’t like health care reform. The biggest one, though, may be how hard it is to see over a cliff—the patent cliff that is resetting valuations across the Big Pharma sector.